Antithrombotic Management of Acute Mesenteric Ischaemia

Conditions: Acute Mesenteric Ischemia, Short Bowel Syndrome

Sex: All

Healthy volunteers: 1

Enrollment: 50

Sponsor: Universitaire Ziekenhuizen KU Leuven

Summary

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

Eligibility Criteria

Inclusion Criteria:gastro-enterologist or cardiologist with expertise in treating SBS patients resulting from AMIExclusion Criteria:none

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05706012). StuddyBuddy aggregates publicly available trial information.